The road to starting up and funding a new biopharmaceutical venture is paved with plenty of speedbumps, but certain big pharma companies and investors have made efforts to smooth the path for start-ups that they view as having a good chance of growing into substantial contributors to the industry. Eli Lilly and Company recently opened its first Gateway Labs location outside of San Francisco and the Deerfield Management-backed health care innovation campus known as Cure in New York City is filling up.
Scrip spoke with executives in charge of Gateway Labs and Cure at the recent BIO International Convention in San Diego about progress at both of the campus-style accelerators, which follow...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
